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Objectives This study sought to evaluate the long-term angiographic and clinical outcomes after
the treatment of drug-eluting stent in-stent restenosis (DES-ISR) based on the angiographic pattern
of restenosis.
Background Long-term outcomes after percutaneous treatment of DES-ISR are unclear.
Methods This study performed a retrospective analysis of 481 consecutive de novo DES-ISR lesions
(n  392) treated percutaneously between August 2002 and July 2007. The lesions were divided
based on the pattern of restenosis: focal (305; 63.4%), diffuse (120; 24.9%), and occlusive (56; 11.6%).
Results The majority (65%) of patients had angina or ischemia on presentation and 13% had an
acute coronary syndrome. Angiographic follow-up after treatment of DES-ISR was available in 65.5%
of lesions. A second angiographic restenosis occurred in 29.1% of the focal group, 45.8% (p 
0.007) of the diffuse, and 65.6% (p  0.0001) of the occlusive. The pattern of DES-ISR predicted the
pattern of recurrence: occlusive reoccluded in 66.7%; diffuse recurred as diffuse or occlusive in
57.9%; focal as focal in 67.2%. During a median follow-up of 2.97 years (interquartile range: 2.37 to
3.89), major adverse cardiac events occurred in 32.8% of patients with no signiﬁcant differences
among the focal, diffuse, and occlusive groups (30.9%, 38.7%, 31.1%; p  0.38). Diffuse restenosis
was associated with a signiﬁcantly higher target lesion revascularization rate compared with focal
(27.1% vs. 15.8%; p  0.008). A disparity between restenosis (65.6%) and target lesion revasculariza-
tion (18.5%) rates for occlusive DES-ISR suggests that as many recurrent restenoses were occlusive,
they were not retreated.
Conclusions DES-ISR identiﬁes a high-risk cohort that is at an increased risk of events, in particular
repeat revascularization, during long-term follow-up. The initial pattern of restenosis is the most im-
portant predictor of recurrent restenosis or the need for subsequent reintervention. (J Am Coll Car-
diol Intv 2011;4:155–64) © 2011 by the American College of Cardiology Foundation
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156Drug-eluting stents (DES) have dramatically diminished
but not eradicated restenosis and even though they have
resulted in single-digit rates in simple lesions, it is not
unusual to see double-figure rates of restenosis in more
complex lesions and real-world studies (1,2). The wide-
spread use of DES and incorporation into daily practice has
led to significant absolute numbers of patients presenting
with DES failure (3). Although the optimal management
strategy of DES in-stent restenosis (DES-ISR) remains
unclear, repeat percutaneous intervention remains the most
frequently used treatment (1,3–5). However, the long-term
angiographic and clinical outcomes after the percutaneous
treatment of DES-ISR are unknown.
See page 165
Methods
All consecutive patients successfully treated percutaneously
for their first episode of DES-ISR at our centers between
August 2002 and July 2007 were
included in this retrospective
analysis. The study period was
chosen from the first episode of
DES-ISR treated at our institu-
tions and to allow a minimum of
2 years of clinical follow-up on
all patients in the study. Patients
were included in the study at the
time of treatment for their first
episode of DES-ISR after treat-
ment of a de novo lesion, that is,
a de novo DES-ISR occurring in
a de novo lesion. Exclusion cri-
teria included: restenotic DES implanted at the index lesion
to treat bare-metal stent or plain old balloon angioplasty
(POBA) restenosis; previous treatment of a DES-ISR; and
previous brachytherapy to the treated vessel. A previous
episode of bare-metal stent restenosis in another vessel was
not an exclusion criterion but the DES-ISR had to be the
first episode in that patient. In addition, 8 patients with
occlusive restenosis in whom successful recanalization was
not possible were excluded from the current analysis. In
Figure 1, we provide a flow chart describing how patients
were selected for this study.
All patients provided informed consent for the procedure
and subsequent data collection and analysis for research pur-
poses. Procedural anticoagulation and antiplatelet therapy fol-
lowed standard protocols. The choice of treatment strategy was
at the operator’s discretion. Aspirin was continued indefi-
nitely and thienopyridine prescribed for at least 1 month
after POBA and at least 6 to 12 months after repeat DES
implantation. Angiographic follow-up was clinically driven
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
ISR  in-stent restenosis
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
POBA  plain old balloon
angioplasty
ST  stent thrombosis
TLR  target lesion
revascularizationor scheduled at the operator’s discretion. tData collection, end points, and study deﬁnitions. Clinical
ollow-up was performed by telephone contact or office visit
t 1, 6, and 12 months after the index procedure. Angio-
raphic follow-up was clinically driven or scheduled at the
perator’s discretion. Angiographic success was defined as a
nal residual stenosis 20% with TIMI (Thrombolysis In
yocardial Infarction) flow grade 3 (6). DES-ISR was
efined as a luminal diameter stenosis of 50% within a
ES or within 5 mm of the stent edges. The lesions were
ivided according to pattern of restenosis into 3 groups:
ocal, diffuse, and occlusive (7). Focal ISR lesions were
efined as 10 mm in length and positioned at the body of
he stent, the proximal or distal margin, or a combination of
hese sites, whereas diffuse ISR was defined as 10 mm in
ength. Proliferative restenosis was included in the latter
roup because of the low prevalence (only 4 cases) in our
opulation. Occlusive DES-ISR were defined as completely
ccluded stents that were not associated with acute clinical
resentations, such as an acute coronary syndrome or
ccluded DES, in which no intracoronary thrombus was
isible after recanalization.
The clinical end points analyzed were periprocedural
yocardial infarction (MI), death, after-discharge MI, stent
Figure 1. Consort-Type Flow Chart Showing Patient Selection for
This Study
During the study period, 887 drug-eluting stent in-stent restenosis (DES-
ISR) lesions were treated at our institutions, of which 406 were excluded
because of prior treatment with a stent, balloon, or brachytherapy. Another
8 occlusive restenotic lesions were also excluded from this analysis because
successful recanalization was not possible. POBA  plain old balloon
angioplasty.hrombosis (ST), target vessel revascularization, target le-
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157sion revascularization (TLR), and major adverse cardiac events
(MACE). MACE was defined as a composite of death, MI,
and target vessel revascularization during the follow-up
period and was evaluated on a per-patient basis. We also
analyzed TLR separately on a per-lesion basis. All deaths
were considered cardiac unless otherwise documented. We
defined post-procedural non–Q-wave MI as a creatinine
kinase-myocardial band elevation of 3 times the upper
limit of normal (8). Creatinine kinase was routinely mea-
sured after percutaneous coronary intervention in all pa-
tients at both centers. Nonprocedural or after-discharge MI
was defined as an elevation of troponin above the upper
range limit in combination with at least 1 of the following:
symptoms of ischemia; electrocardiographic changes indic-
ative of new ischemia; or the development of pathological Q
waves on electrocardiogram. We defined TLR as repeat
revascularization within the stent or within the 5-mm
borders proximal or distal to the stent edge at the follow-up
angiogram. Target lesion revascularization was considered
ischemic-driven if associated with a positive functional
study result and/or ischemic symptoms and a target lesion
diameter stenosis of 50% by visual estimation, or a target
esion diameter stenosis of 70% with or without docu-
mented ischemia. Multiple TLR was defined as more than
1 TLR of the same restenotic lesion. As many restenotic
lesions, especially reocclusive lesions, may have not been
treated at follow-up because of concerns by the operator of
the futility of this treatment, we were concerned that TLR
would not correctly reflect the outcomes of the different
patterns of DES-ISR. Thus, we defined a new end point for
this study to measure this potential disparity, called theo-
retical TLR. Theoretical TLR was defined as the estimated
TLR if every restenosis was treated, that is, the sum of TLR
plus untreated angiographic restenosis. To clarify this dis-
parity, we also calculated the percentage of restenotic lesions
that were treated by dividing the number of TLR by the
total number of lesions with angiographic restenosis. We
defined target vessel revascularization as any repeat revas-
cularization of the target vessel. The definition of ST was in
accordance with the Academic Research Consortium defi-
nitions of definite, probable, possible ST (9).
Statistical methods. Continuous variables are presented as
mean  SD or medians (interquartile range [IQR]) and
categorical variables as frequencies (%). The normality of
the distribution of the continuous variables was tested by
means of the Kolmogorov-Smirnov goodness-of-fit test.
Continuous variables were compared among groups using
analysis of variance with Fisher least-significant difference
post-hoc tests for correction for multiple comparisons.
Categorical variables were compared with chi-square statis-
tic or Fisher exact test where appropriate. Patients lost to
follow-up in whom no event had occurred before the
follow-up windows were not included in the denominator
for calculations of binary end points.Exploratory survival analysis was performed to assess the
impact of restenosis type on the risk of TLR and angio-
graphic restenosis by means of Cox regression analysis using
purposeful selection of covariates (10). Candidate variables
included covariates associated at univariate analysis with
TLR and angiographic restenosis (all with a p value 0.2)
as well as variables judged to be of clinical importance from
previous published literature. Restenosis type was forced
into the multivariable model as an entry criteria because it is
the variable of interest. As observations recorded in the
same patient cannot be considered independent (11), the
sandwich estimator of variance-covariance matrix was em-
ployed to take into account clustered data (more lesions
within the same subject).
The results are reported as adjusted hazard ratios with
associated confidence intervals (CIs). The proportional
hazards assumption of the final model was assessed and
verified (10). Goodness-of-fit of the Cox regression model
was assessed with the Grønnesby-Borgan-May test (12,13).
A p value 0.05 was considered statistically significant, and
all reported p values are 2-sided. Statistical analysis was
performed using Stata software (version 7.0, Stata Corpo-
ration, College Station, Texas).
Results
During the study period, 887 DES-ISR lesions were treated
at our institutions, of which 406 were excluded because of
prior treatment with a stent, balloon, or brachytherapy (Fig. 1).
Thus, a total of 481 lesions in 392 patients that were
successfully treated percutaneously for their first episode of
DES-ISR were analyzed for this study. The pattern of
restenosis was focal in 305 lesions (63.4%), diffuse in 120
(24.9%), and occlusive in 56 (11.6%).
Baseline clinical characteristics of the patients and lesions
treated are presented in Table 1. Clinical characteristics in
patients presenting with different patterns of DES-ISR
were similar except for a higher incidence of insulin-treated
diabetes in diffuse restenosis. The median time from im-
plantation of DES at the index lesion to treatment for
DES-ISR was 224 days (IQR: 175 to 330 days) and was
similar for all 3 patterns of restenosis (p  0.97). The
ajority (65%) of patients treated for DES-ISR in this
tudy had angina or ischemia on presentation. DES-ISR
esulted in an acute coronary syndrome in 13% of patients,
nd this acute presentation was more frequent with diffuse
ather than focal or occlusive restenosis (21.1% vs. 9.2% vs.
4.9%; p 0.012). In patients with occlusive restenosis, the
ndex lesion treated with a DES was more likely to be a
hronic total occlusion (p  0.0001) and possibly as a result
longer stent lengths were implanted (p 0.006). Sirolimus-
eluting and paclitaxel-eluting stents were the most fre-
quently implanted stents during the study period and thus
represented the most frequent stent type in each restenosis
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158Table 1. Baseline Clinical Characteristics of the Patients and the Lesions Treated in the 3 Groups
Overall Focal Diffuse Occlusive p Value
Patients 392 250 95 47 —
Age, yrs 63.9 9.7 63.6 9.3 65.4 10.6 62.1 9.7 0.12
Male 327 (83.4) 215 (86) 74 (77.9) 38 (80.9) 0.17
Ejection fraction, % 53.5 10.2 53.5 9.8 52.7 11.6 55.2 9.3 0.42
Previous MI 163 (41.6) 105 (42) 42 (44.3) 16 (34) 0.50
Previous CABG 103 (26.3) 69 (27.6) 20 (21.1) 14 (29.8) 0.39
Family history 176 (44.9) 108 (43.3) 40 (42.1) 28 (59.6) 0.10
Hypertension 283 (72.2) 183 (73.2) 67 (70.5) 33 (72.2) 0.84
Hypercholesterolemia 294 (75) 188 (75.2) 73 (76.8) 33 (70.2) 0.69
Current smoker 51 (13) 34 (13.6) 11 (11.6) 6 (12.8) 0.88
Diabetes mellitus 146 (37.2) 84 (33.6) 41 (43.2) 21 (44.7) 0.14
Diet-controlled 13 (3.3) 8 (3.2) 2 (2.1) 3 (6.4) 0.40
Oral therapy 87 (22.2) 54 (21.6) 20 (21.1) 13 (27.7) 0.63
Insulin therapy 46 (11.7) 22 (8.8) 19 (20) 5 (10.6) FvD 0.004
FvO 0.68
DvO 0.16
Clinical presentation
ACS 50 (12.8) 23 (9.2) 20 (21.1) 7 (14.9) FvD 0.003
FvO 0.25
DvO 0.3
Stable angina 120 (30.6) 73 (29.2) 35 (36.8) 12 (25.5) FvD 0.17
FvO 0.6
DvO 0.17
Silent ischemia 85 (21.7) 57 (22.8) 14 (14.7) 14 (29.8) FvD 0.09
FvO 0.3
DvO 0.03
Planned angiographic follow-up 137 (34.9) 97 (38.8) 26 (27.4) 14 (29.8) FvD 0.05
FvO 0.24
DvO 0.76
Lesions 481 305 120 56 —
Lesion characteristics at initial
DES implantation
— — — — —
Bifurcation 123 (25.6) 88 (28.9) 28 (23.3) 7 (12.7) FvD 0.25
FvO 0.01
DvO 0.1
Chronic total occlusion 75 (15.6) 33 (10.8) 22 (18.3) 20 (36.4) FvD 0.04
FvO <0.0001
DvO 0.001
Details of DES that restenosed
SES, n (%) [% of SES] 271 (56.3) 194 (63.6) [71.6] 54 (45) [19.9] 23 (41.1) [8.5] FvD <0.0001
FvO 0.002
DvO 0.62
PES, n (%) [% of PES] 189 (39.3) 103 (33.8) [54.5] 56 (46.7) [29.6] 30 (53.6) [15.9] FvD 0.01
FvO 0.005
DvO 0.39
ZES, n (%) [% of ZES] 14 (2.9) 5 (1.6) [35.7] 7 (5.8) [50] 2 (3.6) [14.3] FvD 0.02
FvO 0.33
DvO 0.52
TES, n (%) [% of TES] 7 (1.5) 3 (1) [42.9] 3 (2.5) [42.9] 1 (1.8) [14.3] 0.49
Stent diameter, mm 2.84 0.36 2.85 0.34 2.85 0.37 2.74 0.41 0.20
Stent length, mm 28.66 13.34 27.46 12.64 29.53 12.66 33.74 17.15 FvD 0.17
FvO 0.002
DvO 0.06
Data are presented as absolute numbers and percentages or mean SD, unless otherwise specified. Bold p values are statistically significant.
ACS acute coronary syndrome; CABG coronary artery bypass graft; DESdrug-eluting stent(s); DvOdiffuse versus occlusive; FvD focal versus diffuse; FvO focal versus occlusive;MImyocardialinfarction; PES paclitaxel-eluting stent(s); SES sirolimus-eluting stent(s); TES tacrolimus-eluting stent(s); ZES zotarolimus-eluting stent(s).
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159pattern. In comparison with sirolimus-eluting stents,
paclitaxel-eluting stents were more frequently associated
with diffuse (29.6% vs. 19.9%; p  0.02) and occlusive
estenosis (15.9% vs. 8.5%; p  0.02) but less frequently
ith focal restenosis (54.5% vs. 71.6%; p  0.0001).
Procedural characteristics are displayed in Table 2. DES-
SR was treated more often with repeat DES implantation
ather than balloon angioplasty in all types of restenosis (p 0.05
or all comparisons). In diffuse and occlusive restenosis, the
perator was more likely to implant a DES that eluted a
ifferent drug to the one that restenosed. Intravascular
ltrasound usage was similar in the 3 groups.
Angiographic follow-up was available in 315 lesions
65.5%): 200 lesions (65.6%) in the focal group; 83 lesions
69.2%) in the diffuse group; and 32 lesions (57.1%) in the
cclusive group (p  0.30). Angiographic outcomes and
atterns of recurrent restenosis are shown in Figure 2 and
able 3. There was a highly significant difference in restenosis
ates after treatment between the groups, with a much
igher recurrent restenosis in the occlusive (65.6%) and
iffuse (45.8%) groups. In general, in all 3 groups, the same
r a worse pattern of restenosis recurred in two-thirds of the
estenotic lesions, that is, two-thirds of focal lesions re-
urred as focal ISR, two-thirds of occlusive ISR reoccluded,
nd about two-thirds of diffuse lesions recurred as diffuse or
cclusive restenosis. The rate of recurrent restenosis was
imilar in diabetics versus nondiabetics (35.2% vs. 38.4%;
 0.65). For the focal restenosis group, which represents
he largest subgroup in this study, the rate of recurrent
Table 2. Procedural Characteristics of the Lesions Treated
Overall Focal
Lesions, n 481 305
Repeat DES implantation 318 (66.1) 180 (59)
Homo-DES 111 (34.9) 73 (40.6)
Hetero-DES 207 (65.1) 107 (59.4)
BMS implantation 4 (8) 2 (0.7)
POBA 159 (33.1) 123 (40.3)
Max balloon diameter, mm 2.62 1.01 2.61 1.05
Max inﬂation pressure, atm 17.64 5.51 17.67 5.68
Stent diameter, mm 3.02 0.46 3.07 0.47
Stent length, mm 24.76 13.99 19.13 7.57
IVUS 105 (21.8) 68 (22.3)
Values are presented as n (%) or mean SD. Bold p values are statistically significant.
BMS  bare-metal stent(s); hetero-DES  implantation of stent eluting a different drug; homoPOBA plain old balloon angioplasty; other abbreviations as in Table 1.estenosis was again similar in diabetics versus nondia-
etics (30.6% vs. 28.1%; p  0.84). Furthermore, the rate
f recurrent restenosis after treatment of focal DES-ISR
as similar after POBA (42.4% vs. 36%; p  0.72) and
epeat DES implantation (20.5% vs. 23.4%; p  0.91) in
iabetics versus nondiabetics, respectively.
Clinical follow-up was available in 387 (99%) patients with
median follow-up time of 2.97 years (IQR: 2.37 to 3.89
ears) and 2 years of follow-up available in 95% of eligible
atients. The duration of clinical follow-up was not statistically
ifferent between the 3 groups (p  0.41). There were no
n-hospital deaths or periprocedural revascularizations and the
ate of periprocedural MI was similar in the 3 groups (Table 4).
bout one-third of patients with DES-ISR experienced a
ACE during long-term follow-up, irrespective of the pattern
f restenosis treated at initial presentation. There were no
ignificant differences between the groups in the rates of death
r MI. The rates of TLR were significantly higher for diffuse
ompared with focal DES-ISR, both when calculated per-
atient (28% vs. 16.5%; relative risk [RR]: 1.7, 95% CI: 1.11 to
.61; p 0.02) and per-lesion (27.1% vs. 15.8%; RR: 1.7, 95%
I: 1.16 to 2.55; p 0.008). Although restenosis rates were
ighest for the occlusive group, TLR rates were not con-
ordantly high, suggesting that many recurrent restenoses
ere not retreated. Indeed only 47.6% of occlusive DES-
SR were retreated in comparison with 82.6% focal and
4.2% of diffuse restenoses. We also calculated what the
heoretical TLR rate would have been if every restenosis had
een treated. The difference between actual and theoretical
Diffuse Occlusive p Value
120 56 —
89 (74.2) 49 (87.5) FvD 0.004
FvO <0.0001
DvO 0.045
26 (29.2) 12 (24.5) FvD 0.07
63 (70.8) 37 (75.5) FvO 0.04
DvO 0.55
2 (1.7) 0 <0.0001
29 (24.2) 7 (12.5) FvD 0.002
FvO <0.0001
DvO 0.13
2.68 0.92 2.49 0.93 0.50
17.46 4.95 17.87 5.80 0.89
3.05 0.41 2.77 0.43 FvD 0.81
FvO <0.0001
DvO 0.001
28.48 11.79 39.08 22.06 FvD <0.0001
FvO <0.0001
DvO <0.0001
27 (22.5) 10 (17.9) 0.74
implantation of stent eluting the same drug; IVUS  intravascular ultrasound; max  maximum;-DES 
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160TLR rates was approximately 5% for the focal and diffuse
groups, but was about 20% for the occlusive restenosis
group, again confirming that many occlusive restenoses were
not retreated (Fig. 3).
In relation to antiplatelet therapy, 56% of patients were
still receiving dual antiplatelet therapy at 1 year after
treatment of the restenosis. The median time to dual
antiplatelet therapy discontinuation was 356 days (IQR:
Figure 2. Patterns of Recurrent Angiographic Restenosis According to the
For each of the initial patterns of restenosis, the rate of recurrent restenosis af
the bar graph. Abbreviations as in Figure 1.
Table 3. Angiographic Outcomes Based on the Pattern of Restenosis
Overall F
Lesions with angiographic follow-up, n 315
Time-to-angiographic documentation
of restenosis, median [IQR]
299 [180–539] 349 [
Angiographic restenosis 117 (37.1) 58
Recurrent restenosis pattern
Focal 60 (51.3) 39
Diffuse 29 (24.8) 12
Occlusive 28 (23.9) 7
Values are presented as n (%) or median (interquartile range). Bold p values are statistically significAbbreviations as in Tables 1 and 2.180 to 413 days). According to the Academic Research
Consortium definition of ST, the overall rate of definite/
probable ST was 1.3% after the treatment of DES-ISR.
There were 2 (0.5%) cases of very late definite ST, which
both occurred in the focal DES-ISR group, at 757 days
(on dual antiplatelet therapy) and at 1,185 days (only on
aspirin), both after repeat DES implantation. The 3 cases
of probable ST (2 in the focal and 1 in diffuse DES-ISR
l Pattern of Restenosis
atment of DES-ISR is shown as a pie chart with the pattern of recurrence in
Diffuse Occlusive p Value
83 32 —
8] 267 [179–480] 181 [93–309] 0.007
38 (45.8) 21 (65.6) FvD 0.007
FvO <0.0001
DvO 0.056
16 (42.1) 5 (23.8) FvD 0.02
FvO 0.001
DvO 0.16
15 (39.5) 2 (9.5) FvD 0.045
FvO 0.25
DvO 0.02
7 (18.4) 14 (66.7) FvD 0.38
FvO <0.0001
DvO <0.0001Initia
ter treocal
200
188–67
(29.0)
(67.2)
(20.7)
(12.1)
ant.
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161group) were adjudicated due to the occurrence of an acute
MI in the territory of the treated restenotic lesion.
Multivariable Cox regression analysis was used to
identify independent predictors of TLR and recurrent
restenosis. The candidate variables assessed, the results of
the final multivariable that included only significant
independent predictors or important confounders, and
the p value for the goodness-of-fit test of the propor-
tional hazards model are shown in Table 5. Diffuse
restenosis (hazard ratio [HR]: 2.05, 95% CI: 1.30 to
3.22; p  0.02) and previous bypass surgery were the only
independent predictors of TLR. However, for recurrent
restenosis, both diffuse (HR: 2.19, 95% CI: 1.42 to 3.38;
p  0.0001) and occlusive (HR: 4.86, 95% CI: 2.82 to
8.34; p  0.0001) patterns of restenosis as well as
Table 4. In-Hospital and Follow-Up Clinical Events in the Overall Cohort an
Overall
Patients, n 392
In-hospital events
Periprocedural myocardial
infarction
9 (2.3)
Death 0
Acute thrombosis 0
Cumulative events* 387
MACE 127 (32.8)
Death 25 (6.5)
Cardiac death 17 (4.4)
MI 18 (4.7)
TVR 105 (27.1)
TLR (per patient) 77 (19.9)
TLR (per lesion) 90/476 (18.9) 48/
t-TLR (per lesion) 119/476 (25.0) 60/
Ratio of TLR/restenosis (per lesion) 90/117 (76.9) 48
Multiple TLR (per patient) 18 (4.7)
Multiple TLR (per lesion) 21/476 (4.4) 10/
ARC stent thrombosis
Deﬁnite ST 2 (0.5)
Probable ST 3 (0.8)
Deﬁnite/probable ST 5 (1.3)
Values are presented as n (%). Bold p values are statistically significant. *Except periprocedural MI.
ARC Academic Research Consortium; MACEmajor adverse cardiac event(s); ST stent throm
other abbreviations as in Tables 1, 2, and 3.previous bypass surgery were predictive, whereas repeatDES implantation was associated with a 50% (95% CI:
25% to 66%; p  0.001) reduction in restenosis.
Discussion
The main findings of this study of the long-term outcomes
of the treatment of DES-ISR are: 1) DES failure identifies
a group of patients who are at high risk of future events after
treatment, in particular repeat revascularization; 2) the
pattern of DES-ISR is an important predictor of the
occurrence and pattern of recurrent restenosis, as well as the need
for subsequent reintervention; and 3) treatment of DES-
ISR with repeat DES implantation appears to be associated
with a reduction in recurrent restenosis and does not seem
estenosis Pattern
Diffuse Occlusive p Value
95 47
) 3 (3.2) 1 (2.1) 0.81
0 0 —
0 0 —
93 45
0.9) 36 (38.7) 14 (31.1) 0.381
) 6 (6.5) 4 (8.9) 0.77
.8) 2 (2.2) 3 (6.7) 0.41
.2) 2 (2.2) 3 (6.7) 0.39
4.9) 32 (34.4) 11 (24.4) 0.19
6.5) 26 (28) 10 (22.2) FvD 0.02
FvO 0.34
DvO 0.47
5.8) 32/118 (27.1) 10/54 (18.5) FvD
0.008
FvO 0.61
DvO 0.22
9.7) 38/118 (32.2) 21/54 (38.9) FvD
0.006
FvO
0.002
DvO 0.39
2.6) 32/38 (84.2) 10/21 (47.6) FvD 0.85
FvO
0.005
DvO
0.008
) 7 (7.5) 1 (2.2) 0.278
.3) 10/118 (8.5) 1/54 (1.9) 0.04
.8) 0 0 0.57
.8) 1 (1.1) 0 0.79
.6) 1 (1.1) 0 0.67
LR target lesion revascularization; t-TLR theoretical TLR; TVR target vessel revascularization;d by R
Focal
250
5 (2
0
0
249
77 (3
15 (6
12 (4
13 (5
62 (2
41 (1
304 (1
304 (1
/58 (8
10 (4
304 (3
2 (0
2 (0
4 (1
bosis; Tto influence the risk of late stent thrombosis.
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162In a previous study from our center (14) of 250 DES-ISR
lesions, we demonstrated that nonfocal DES-ISR is predic-
tive of TLR at medium-term follow-up. A number of
studies have examined the outcomes after the treatment of
DES-ISR but many have been limited by the lack of
adequate angiographic follow-up (15–18), small sample
sizes (5,19,20), or short follow-up periods (16,18). In this
study, we report the angiographic and clinical long-term
outcomes of 481 de novo DES-ISR lesions after their first
percutaneous treatment, analyzed based on the pattern of
restenosis. Similar to bare-metal stent restenosis (21), DES-
ISR is not a benign entity as it presents as an acute coronary
syndrome in 13% of patients overall and in up to 20% of
Figure 3. Rates of Actual TLR and t-TLR for the 3 Groups of
Restenosis Patterns
The bar graph demonstrates the rates of actual target lesion revasculariza-
tion (TLR) and theoretical TLR (t-TLR) calculated per lesion for the overall
cohort and for each pattern of restenosis. Theoretical-TLR was deﬁned as
the estimated TLR if every restenosis was treated, that is, the sum of TLR
plus untreated angiographic restenosis.
Table 5. Multivariable Analysis for Predictors of TLR (Per-Lesion) and Angi
End Point Univariate Predictors Assessed
Target lesion
revascularization
Restenosis type, restenotic DES length, previous
MI, previous CABG, hypertension,
hypercholesterolemia, diabetes, presenting
symptoms, ejection fraction, repeat DES
implantation, restenotic DES type, stent
length, intravascular ultrasound
Diffus
Occlus
Previo
Resten
(per 1
Recurrent angiographic
restenosis
Restenosis type, occlusive index lesion,
bifurcation index lesion, restenotic DES
length, restenotic DES diameter, age,
previous CABG, diabetes, ejection fraction,
repeat DES implantation, restenotic DES type,
stent length, minimum lumen diameter
Diffus
Occlus
Previo
RepeaISR in-stent restenosis; other abbreviations as in Tables 1 and 4.patients with diffuse restenosis. Furthermore, this study
confirms that DES-ISR identifies a high-risk cohort that
have failed our best available antirestenotic therapy and
that will have a significant recurrence and MACE rate with
repeat percutaneous intervention. Indeed, in this study, 1 of
3 patients treated for DES-ISR had an event during a
median follow-up period of 3 years, irrespective of the initial
pattern of restenosis. As a result, coronary artery bypass
surgery may be considered as a viable treatment alternative
for complex DES restenosis, particularly when it occurs in
the left main or left anterior descending coronary arteries (1).
This study confirms the prognostic importance of the
pattern of DES-ISR, which not only predicted the recur-
rence of restenosis but also the pattern. In comparison with
focal DES-ISR, recurrent restenosis after percutaneous
treatment occurs 2.2 times more often with diffuse resteno-
sis and 4.9 times more frequently with occlusive restenosis.
Also, an aggressive pattern of restenosis begets aggressive
restenosis after treatment, that is, occlusive ISR will reoc-
clude in two-thirds and diffuse restenosis will recur as
diffuse or occlusive restenosis in about two-thirds of recur-
rent restenoses cases. It is noteworthy that both on univar-
iate and multivariable analysis, the presence of diabetes
mellitus did not influence the rate of recurrent restenosis
after the treatment of DES-ISR. We believe that this may
be because the occurrence of DES-ISR identifies a high-risk
lesion-patient cohort with a higher rate of recurrent events,
where the presence of diabetes may no longer confer an
additive risk.
These data also provide valuable insights into the most
aggressive pattern of restenosis. In comparison with the
other patterns of restenosis, in lesions with occlusive DES-
ISR, the index lesion was more often a chronic total
occlusion (36.4%), with longer stents implanted at the index
procedure, and the DES-ISR was treated with longer stents
hic Restenosis
Final Multivariable Model
able
Hazard
Ratio
95% Confidence
Interval p Value
Grønnesby-Borgan-May
Goodness-of-Fit
p Value
cal ISR
. focal ISR
G
ES length
of stent)
2.05
1.45
1.58
0.98
1.30–3.22
0.70–3.00
1.01–2.48
0.86–1.11
0.002
0.32
0.04
0.74
0.64
cal ISR
. focal ISR
G
implantation
2.19
4.86
1.52
0.50
1.42–3.38
2.82–8.34
1.03–2.25
0.34–0.75
0.0001
0.0001
0.04
0.001
0.63ograp
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163(39.08  22.06 mm). Although occlusive DES-ISR was
highly predictive of recurrent restenosis, it was not associ-
ated with the need for repeat revascularization on univariate
or multivariable analysis. Indeed, there was a marked
disparity between restenosis (66.7%) and TLR (18.5%) rates
for the occlusive group, which led us to define a new end
point for this study, that is, the theoretical TLR if every
restenosis was treated. The theoretical TLR was 38.9% and
as can be seen in Figure 3, there was again a marked
discordance between actual and theoretical TLR for the
occlusive group. In fact, less than one-half of occlusive
restenoses were retreated, whereas over 80% of focal and
diffuse restenoses underwent repeat revascularization. We
believe that these data confirm that as occlusive DES-ISR
most often recurs as a reocclusion, operators often decide
not to repeat percutaneous intervention because of the
perceived futility of this procedure. It is interesting to note
that in the occlusive group, only focal recurrent restenoses
were retreated whereas recurrent occlusive restenoses were
left untreated.
The optimal percutaneous treatment of DES-ISR still
remains unclear, that is, conventional angioplasty versus
repeat DES for focal DES-ISR; or implanting a DES with
a different drug (hetero-DES) versus the same drug (homo-
DES). The only randomized trial performed (ISAR-
DESIRE 2 [Intracoronary Stenting and Angiographic Re-
sults: Drug Eluting Stents for In-Stent Restenosis 2] study)
(3) demonstrated that in sirolimus-eluting stent restenosis,
treatment with either repeat sirolimus-eluting stent or
switching to a paclitaxel-eluting stent was associated with a
comparable degree of efficacy or safety. Our study does not
clarify the appropriate strategy for treating DES-ISR, but it
does reinforce the concept that when treating DES reste-
nosis we should make every attempt to optimize the final
result and not fail the second time (1). Multivariable analysis
did confirm that repeat DES implantation was effective in
reducing recurrent restenosis. This finding seems to hold
even in the focal restenosis group in which repeat DES
implantation was more effective than POBA. Finally, the
effectiveness of new technologies such as drug-eluting bal-
loons in treating DES-ISR is not clear.
Study limitations. This study suffers the obvious limitations
inherent to observational nonrandomized registries. Our
rate of angiographic follow-up may also be considered a
limitation particularly when considering the analysis of
recurrent patterns of restenoses after treatment. However,
the rates of angiographic follow-up were similar in the 3
groups and are quite high for a registry study. The results of
this study are applicable only to the first generation of DES.
Because the treatment strategy and choice of stent was at
the operator’s discretion, we did not perform any analysis of
outcomes based on treatment strategy.Conclusions
DES-ISR identifies a high-risk cohort of patients who are
at an increased risk of events after treatment, in particular
repeat revascularization, during long-term follow-up. The
initial pattern of restenosis is the most important predictor
of recurrent restenosis or the need for subsequent reinter-
vention. Repeat DES implantation appears to be a viable
alternative while awaiting the promising results of new
technologies such as drug-eluting balloons.
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